


Poland, Kielce (2013–2017)

CI5 Volume XII (editorial table 1)
Population pyramids



613716

Total

644130

624133

Vol. XI (2008–2012) grayed pyramid

655673

XII/XI 0.98

XII/XI 0.98

Poland, Kielce (2013–2017)

C15 Volume XII (editorial table 2)


Number of cases in major diagnosis groups in single calendar years of observation

SITE	MALE					
	2013	2014	2015	2016	2017	Total
Lip, oral cavity and pharynx (C00–14)	108 (4.0)	99 (3.6)	112 (3.9)	116 (3.9)	112 (3.8)	547 (3.8)
Digestive organs (C15–26)	653 (24.2)	674 (24.3)	671 (23.4)	629 (21.0)	697 (23.5)	3324 (23.3)
Respiratory organs (C30–39)	668 (24.7)	717 (25.9)	646 (22.5)	664 (22.2)	581 (19.6)	3276 (22.9)
Bone, cartilage, melanoma (C40–43)	61 (2.3)	72 (2.6)	77 (2.7)	73 (2.4)	70 (2.4)	353 (2.5)
Male genital (C60–63)	511 (18.9)	544 (19.6)	628 (21.9)	741 (24.8)	761 (25.7)	3185 (22.3)
Urinary organs (C64–68, D09.0+D41.4)	310 (11.5)	309 (11.2)	363 (12.6)	367 (12.3)	362 (12.2)	1711 (12.0)
Eye, brain, thyroid etc. (C69–75)	90 (3.3)	79 (2.9)	112 (3.9)	105 (3.5)	105 (3.5)	491 (3.4)
Haematopoietic (C81–96, D45–47)	219 (8.1)	200 (7.2)	197 (6.9)	218 (7.3)	192 (6.5)	1026 (7.2)
Other and unspecified	81 (3.0)	77 (2.8)	64 (2.2)	80 (2.7)	80 (2.7)	382 (2.7)
All sites but skin (C00–96bC44, DXX.X)	2701 (100.0)	2771 (100.0)	2870 (100.0)	2993 (100.0)	2960 (100.0)	14295 (100.0)

SITE	FEMALE					
	2013	2014	2015	2016	2017	Total
Lip, oral cavity and pharynx (C00–14)	39 (1.7)	32 (1.4)	39 (1.6)	34 (1.3)	31 (1.3)	175 (1.4)
Digestive organs (C15–26)	468 (20.3)	454 (19.2)	513 (21.1)	489 (19.1)	507 (20.5)	2431 (20.0)
Respiratory organs (C30–39)	203 (8.8)	223 (9.4)	208 (8.5)	266 (10.4)	264 (10.7)	1164 (9.6)
Bone, cartilage, melanoma (C40–43)	75 (3.3)	60 (2.5)	77 (3.2)	87 (3.4)	95 (3.8)	394 (3.2)
Female breast (C50)	531 (23.0)	515 (21.8)	572 (23.5)	569 (22.2)	538 (21.7)	2725 (22.5)
Female genital (C51–58)	440 (19.1)	480 (20.3)	448 (18.4)	458 (17.9)	429 (17.3)	2255 (18.6)
Urinary organs (C64–68, D09.0+D41.4)	128 (5.6)	137 (5.8)	147 (6.0)	173 (6.7)	145 (5.9)	730 (6.0)
Eye, brain, thyroid etc. (C69–75)	168 (7.3)	190 (8.0)	222 (9.1)	233 (9.1)	218 (8.8)	1031 (8.5)
Haematopoietic (C81–96, D45–47)	178 (7.7)	203 (8.6)	163 (6.7)	183 (7.1)	175 (7.1)	902 (7.4)
Other and unspecified	74 (3.2)	67 (2.8)	44 (1.8)	72 (2.8)	73 (2.9)	330 (2.7)
All sites but skin (C00–96bC44, DXX.X)	2304 (100.0)	2361 (100.0)	2433 (100.0)	2564 (100.0)	2475 (100.0)	12137 (100.0)

SITE	BOTH SEXES					
	2013	2014	2015	2016	2017	Total
Lip, oral cavity and pharynx (C00–14)	147 (2.9)	131 (2.6)	151 (2.8)	150 (2.7)	143 (2.6)	722 (2.7)
Digestive organs (C15–26)	1121 (22.4)	1128 (22.0)	1184 (22.3)	1118 (20.1)	1204 (22.2)	5755 (21.8)
Respiratory organs (C30–39)	871 (17.4)	940 (18.3)	854 (16.1)	930 (16.7)	845 (15.5)	4440 (16.8)
Bone, cartilage, melanoma (C40–43)	136 (2.7)	132 (2.6)	154 (2.9)	160 (2.9)	165 (3.0)	747 (2.8)
Urinary organs (C64–68, D09.0+D41.4)	438 (8.8)	446 (8.7)	510 (9.6)	540 (9.7)	507 (9.3)	2441 (9.2)
Eye, brain, thyroid etc. (C69–75)	258 (5.2)	269 (5.2)	334 (6.3)	338 (6.1)	323 (5.9)	1522 (5.8)
Haematopoietic (C81–96, D45–47)	397 (7.9)	403 (7.9)	360 (6.8)	401 (7.2)	367 (6.8)	1928 (7.3)
Other and unspecified	155 (3.1)	144 (2.8)	108 (2.0)	152 (2.7)	153 (2.8)	712 (2.7)
All sites but skin (C00–96bC44, DXX.X)	5005 (100.0)	5132 (100.0)	5303 (100.0)	5557 (100.0)	5435 (100.0)	26432 (100.0)

ALL SITES EXCEPT NON-MELANOMA SKIN - BOTH SEXES					
2013	2014	2015	2016	2017	



Poland, Kielce (2013–2017)


C15 Volume XII (editorial table 2) ASR in major diagnosis groups in single calendar years of observation

SITE	MALE					
	2013	2014	2015	2016	2017	Total
Lip, oral cavity and pharynx (C00–14)	10.5 (4.1)	9.4 (3.7)	11.2 (4.2)	10.9 (4.1)	10.3 (4.0)	10.5 (4.0)
Digestive organs (C15–26)	60.2 (23.6)	59.4 (23.3)	59.7 (22.6)	54.7 (20.4)	59.8 (23.0)	58.7 (22.5)
Respiratory organs (C30–39)	61.3 (24.0)	65.1 (25.5)	56.9 (21.5)	57.2 (21.4)	49.0 (18.8)	57.9 (22.2)
Bone, cartilage, melanoma (C40–43)	6.9 (2.7)	6.5 (2.6)	7.7 (2.9)	7.4 (2.8)	6.1 (2.3)	7.0 (2.7)
Male genital (C60–63)	46.4 (18.1)	50.6 (19.8)	56.2 (21.2)	63.7 (23.8)	64.6 (24.8)	56.6 (21.7)
Urinary organs (C64–68, D09.0+D41.4)	28.7 (11.2)	27.5 (10.8)	32.5 (12.3)	31.7 (11.9)	31.7 (12.2)	30.5 (11.7)
Eye, brain, thyroid etc. (C69–75)	10.2 (4.0)	8.4 (3.3)	13.2 (5.0)	12.0 (4.5)	11.2 (4.3)	11.0 (4.2)
Haematopoietic (C81–96, D45–47)	23.0 (9.0)	20.7 (8.1)	21.4 (8.1)	22.1 (8.3)	20.5 (7.9)	21.5 (8.2)
Other and unspecified	8.4 (3.3)	7.6 (3.0)	5.9 (2.2)	7.8 (2.9)	7.1 (2.7)	7.3 (2.8)
All sites but skin (C00–96bC44, DXX.X)	255.5 (100.0)	255.2 (100.0)	264.7 (100.0)	267.5 (100.0)	260.4 (100.0)	260.8 (100.0)

SITE	FEMALE					
	2013	2014	2015	2016	2017	Total
Lip, oral cavity and pharynx (C00–14)	3.1 (1.7)	2.3 (1.2)	2.9 (1.5)	2.6 (1.3)	2.2 (1.1)	2.6 (1.3)
Digestive organs (C15–26)	31.4 (16.7)	29.7 (15.5)	34.0 (17.3)	31.5 (15.3)	33.2 (16.9)	31.9 (16.3)
Respiratory organs (C30–39)	15.4 (8.2)	16.3 (8.5)	15.4 (7.8)	19.9 (9.7)	18.5 (9.4)	17.2 (8.8)
Bone, cartilage, melanoma (C40–43)	6.0 (3.2)	4.6 (2.4)	5.9 (3.0)	7.8 (3.8)	8.7 (4.4)	6.6 (3.4)
Female breast (C50)	48.1 (25.6)	45.6 (23.8)	49.4 (25.1)	50.1 (24.4)	45.6 (23.2)	47.8 (24.4)
Female genital (C51–58)	35.5 (18.9)	40.1 (20.9)	36.9 (18.7)	37.4 (18.2)	35.0 (17.8)	37.0 (18.9)
Urinary organs (C64–68, D09.0+D41.4)	9.9 (5.2)	10.4 (5.4)	11.8 (6.0)	12.4 (6.0)	10.4 (5.3)	11.0 (5.6)
Eye, brain, thyroid etc. (C69–75)	18.6 (9.9)	21.3 (11.1)	24.6 (12.5)	25.1 (12.2)	23.4 (11.9)	22.6 (11.5)
Haematopoietic (C81–96, D45–47)	14.9 (7.9)	16.2 (8.5)	13.3 (6.7)	14.0 (6.8)	14.5 (7.4)	14.6 (7.4)
Other and unspecified	5.1 (2.7)	5.0 (2.6)	3.0 (1.5)	5.1 (2.5)	5.2 (2.7)	4.7 (2.4)
All sites but skin (C00–96bC44, DXX.X)	188.0 (100.0)	191.5 (100.0)	197.2 (100.0)	205.8 (100.0)	196.7 (100.0)	195.8 (100.0)

SITE	BOTH SEXES					
	2013	2014	2015	2016	2017	Total
Lip, oral cavity and pharynx (C00–14)	6.6 (3.1)	5.6 (2.6)	6.9 (3.1)	6.5 (2.8)	6.0 (2.7)	6.3 (2.9)
Digestive organs (C15–26)	43.8 (20.4)	42.5 (19.7)	45.2 (20.2)	41.7 (18.2)	45.0 (20.3)	43.6 (19.7)
Respiratory organs (C30–39)	35.8 (16.7)	38.0 (17.6)	33.7 (15.1)	36.4 (15.8)	32.0 (14.5)	35.2 (15.9)
Bone, cartilage, melanoma (C40–43)	6.5 (3.0)	5.4 (2.5)	6.7 (3.0)	7.5 (3.3)	7.3 (3.3)	6.7 (3.0)
Urinary organs (C64–68, D09.0+D41.4)	18.0 (8.4)	17.8 (8.2)	20.7 (9.3)	20.8 (9.1)	19.8 (8.9)	19.5 (8.8)
Eye, brain, thyroid etc. (C69–75)	14.3 (6.7)	14.8 (6.9)	18.8 (8.4)	18.5 (8.1)	17.1 (7.7)	16.7 (7.6)
Haematopoietic (C81–96, D45–47)	18.5 (8.6)	18.2 (8.4)	16.9 (7.6)	17.8 (7.7)	17.4 (7.9)	17.7 (8.0)
Other and unspecified	6.6 (3.1)	6.1 (2.8)	4.3 (1.9)	6.3 (2.7)	6.0 (2.7)	5.8 (2.6)
All sites but skin (C00–96bC44, DXX.X)	214.3 (100.0)	216.1 (100.0)	223.2 (100.0)	229.4 (100.0)	221.2 (100.0)	220.9 (100.0)


ALL SITES EXCEPT NON-MELANOMA SKIN - BOTH SEXES



Population denominator available for each of the 5 years


Poland, Kielce (2013–2017)

CI5 Volume XII (editorial table 3)
Age-specific rates graphs for major diagnosis groups



Poland, Kielce (2013–2017)

C15 Volume XII (editorial table 3)
Age-specific rates graphs for major diagnosis groups



Poland, Kielce (2013–2017)

C15 Volume XII (editorial table 4)

ANNUAL INCIDENCE PER 100,000 BY AGE GROUP (YEARS) – MALE

S I T E	ALL AGE AGES UNK	0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80–	85+	CRUDE RATE	(%)	MV (%)	ASR (W)	*CH V11	ICD (10th)	
Lip	83	0	–	–	–	–	–	–	–	0.4	–	1.0	4.2	5.4	12.1	7.5	13.3	26.1	19.1	2.7	0.6	100	1.3	-7.3	C00	
Tongue	88	0	–	–	–	–	–	–	–	1.8	4.1	5.9	9.8	6.8	9.1	9.7	–	3.7	–	2.9	0.6	100	1.8	11.5	C01-02	
Mouth	85	0	–	–	–	–	–	–	0.4	0.4	5.7	4.4	8.9	7.7	7.9	5.4	4.0	1.9	8.2	2.8	0.6	98	1.7	-2.6	C03-06	
Salivary glands	37	0	–	–	–	–	0.5	–	–	0.8	0.4	1.0	1.0	2.5	0.9	3.0	1.1	8.0	13.0	5.5	1.2	0.3	97	0.6	-5.8	C07-08
Tonsil	51	0	–	–	–	–	–	–	–	0.9	1.0	2.5	5.5	5.0	6.1	4.3	2.7	1.9	2.7	1.7	0.4	96	1.0	19.4	C09	
Other oropharynx	85	0	–	–	–	–	–	–	–	0.8	2.2	3.6	4.0	8.1	10.4	5.5	7.5	2.7	5.6	–	2.8	0.6	100	1.7	1.4	C10
Nasopharynx	24	0	–	–	–	–	–	–	–	0.4	0.9	–	2.0	0.8	0.9	3.0	5.4	–	5.6	–	0.8	0.2	100	0.5	-5.9	C11
Hypopharynx	87	0	–	–	–	–	–	–	–	1.3	0.5	6.9	9.8	9.5	8.5	5.4	6.7	1.9	–	2.8	0.6	97	1.7	8.8	C12-13	
Pharynx unspecified	7	0	–	–	–	–	–	–	–	–	0.5	0.5	1.3	–	0.6	1.1	–	–	–	0.2	0.0	71	0.1	-17.9	C14	
Oesophagus	190	0	–	–	–	–	0.8	–	0.4	1.8	3.1	6.9	10.6	30.8	21.8	12.9	14.7	13.0	10.9	6.2	1.3	97	3.6	-1.7	C15	
Stomach	642	0	–	–	0.7	0.6	0.5	0.8	1.2	1.6	2.7	10.3	16.8	23.8	48.9	61.3	105.3	122.7	121.0	20.9	4.5	96	11.4	-2.5	C16	
Small intestine	14	0	–	–	–	–	–	–	0.4	–	0.4	0.5	–	0.8	1.4	–	2.1	2.7	–	5.5	0.5	0.1	93	0.3	-14.4	C17
Colon	1005	0	–	–	–	0.6	–	0.4	1.5	1.2	4.0	10.9	18.3	37.4	68.3	116.5	161.2	200.0	238.3	191.5	32.8	7.0	97	17.2	-1.7	C18
Rectum	793	0	–	–	–	–	1.0	0.8	0.8	2.0	3.6	11.4	16.8	43.8	59.7	99.5	117.1	141.3	134.0	87.5	25.8	5.5	99	14.0	-1.5	C19-20
Anus	13	0	–	–	–	–	–	–	–	–	–	–	0.5	–	1.8	1.8	3.2	1.3	1.9	–	0.4	0.1	85	0.2	3.5	C21
Liver	235	0	0.7	–	–	–	–	0.4	0.4	–	1.3	4.7	6.4	12.3	18.5	23.7	30.1	40.0	37.2	54.7	7.7	1.6	71	4.2	6.9	C22
Gallbladder etc.	106	0	–	–	–	–	–	–	–	0.4	0.9	2.6	3.5	2.1	10.0	10.9	12.9	21.3	16.8	24.6	3.5	0.7	81	1.9	-0.1	C23-24
Pancreas	311	0	–	–	–	–	–	–	0.8	0.8	2.2	8.3	9.4	15.3	26.2	36.4	37.6	45.3	55.8	38.3	10.1	2.2	82	5.6	-3.3	C25
Nose, sinuses etc.	19	0	–	–	–	–	–	–	0.4	0.4	–	–	1.0	0.4	0.9	3.0	3.2	5.3	–	–	0.6	0.1	100	0.4	1.1	C30-31
Larynx	368	0	–	–	–	–	–	–	0.4	0.4	0.9	3.6	14.8	27.2	46.6	44.9	45.1	32.0	31.6	8.2	12.0	2.6	99	6.8	-3.8	C32
Trachea, bronchus and lung	2859	0	–	–	–	–	0.5	–	1.5	1.2	9.4	23.3	57.3	157.2	263.8	396.7	415.9	473.3	424.4	251.6	93.2	20.0	94	50.2	-2.9	C33-34
Other thoracic organs	25	0	–	–	–	–	–	–	–	0.4	1.0	0.5	1.7	1.8	4.2	2.1	1.3	3.7	2.7	0.8	0.2	88	0.5	-3.5	C37-38	
Bone	54	0	–	–	1.4	1.8	–	1.7	0.4	–	1.8	2.6	–	2.1	0.9	3.6	8.6	9.3	7.4	8.2	1.8	0.4	78	1.3	4.9	C40-41
Melanoma of skin	299	0	–	–	–	–	–	2.1	3.1	5.2	5.4	6.2	8.9	13.2	24.4	29.7	34.4	42.7	37.2	35.6	9.7	2.1	100	5.7	5.8	C43
Other skin	1212	0	–	0.6	–	0.6	–	1.3	2.3	3.2	8.5	18.1	27.2	39.5	61.5	114.0	156.9	266.7	351.8	361.1	39.5	8.5	100	20.3	3.2	C44
Mesothelioma	39	0	–	–	–	–	–	–	–	0.4	1.6	1.5	0.8	4.1	7.3	3.2	4.0	5.6	–	1.3	0.3	100	0.7	-0.7	C45	
Kaposi sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	–	0.5	–	–	1.3	–	–	0.1	0.0	100	0.0	-3.6	C46	
Connective and soft tissue	76	0	3.5	–	0.7	0.6	1.4	1.3	1.2	1.6	1.3	2.6	4.0	3.8	2.3	4.2	5.4	5.3	5.6	19.1	2.5	0.5	96	2.0	1.6	C47+C49
Breast	20	0	–	–	–	–	–	–	–	–	0.5	–	0.4	0.9	1.8	4.3	4.0	7.4	5.5	0.7	0.1	100	0.3	3.3	C50	
Penis	42	0	–	–	–	–	–	–	–	0.9	1.0	1.0	3.0	3.2	3.0	3.2	5.3	14.9	5.5	1.4	0.3	100	0.7	2.2	C60	
Prostate	2950	0	–	–	–	–	–	–	0.4	1.3	7.8	30.1	93.9	221.7	432.5	591.1	606.6	510.0	456.8	96.1	20.6	97	50.4	8.8	C61	
Testis	190	0	0.7	–	–	4.1	8.1	13.5	17.4	13.3	11.2	6.2	2.0	2.1	0.9	2.4	1.1	–	3.7	–	6.2	1.3	98	5.4	4.9	C62
Other male genital organs	3	0	–	–	–	–	–	–	–	–	–	–	0.4	–	1.2	–	–	–	–	0.1	0.0	100	0.1	-2.9	C63	
Kidney	543	0	1.4	1.9	–	–	–	0.4	1.2	2.0	7.2	14.0	20.7	31.4	47.5	61.3	65.6	74.7	55.8	46.5	17.7	3.8	95	10.5	-1.9	C64
Renal pelvis	40	0	–	–	–	–	–	–	–	–	0.9	1.0	1.0	2.1	4.5	6.7	2.1	4.0	3.7	2.7	1.3	0.3	100	0.7	1.4	C65
Ureter	11	0	–	–	–	–	–	–	–	–	–	0.5	0.4	–	3.6	–	4.0	–	–	0.4	0.1	91	0.2	8.9	C66	
Bladder	1116	0	–	–	–	0.6	–	2.1	1.9	0.4	3.1	9.3	18.3	52.7	71.5	132.2	179.5	220.0	236.4	227.0	36.4	7.8	97	19.1	-1.2	C67
Other urinary organs	1	0	–	–	–	–	–	–	–	–	–	–	–	0.5	–	–	–	–	–	0.0	0.0	100	0.0	-22.4	C68	
Eye	31	0	1.4	0.6	–	–	–	0.4	–	0.8	0.9	–	3.0	–	1.4	2.4	3.2	6.7	3.7	–	1.0	0.2	71	0.8	10.9	C69
Brain, nervous system	310	0	2.1	1.9	2.0	0.6	1.9	3.0	3.5	1.6	6.3	9.8	15.3	13.6	20.4	27.9	33.3	32.0	37.2	38.3	10.1	2.2	77	6.7	-3.0	C70-72
Thyroid	137	0	–	–	–	0.6	2.4	3.0	3.1	4.4	5.4	6.7	4.0	9.3	6.8	12.1	7.5	4.0	3.7	8.2	4.5	1.0	99	3.1	7.5	C73
Adrenal gland	7	0	1.4	–	–	–	–	–	–	–	–	–	0.5	0.4	0.5	0.6	–	–	1.9	–	0.2	0.0	86	0.3	23.8	C74
Other endocrine	6	0	–	–	0.7	–	–	–	–	0.4	0.9	–	–	–	0.5	–	1.1	–	–	–	0.2	0.0	83	0.2	7.6	C75
Hodgkin lymphoma	71	0	–	1.3	1.4	3.5	3.3	3.0	3.9	2.8	1.3	3.1	2.0	1.3	2.3	1.2	3.2	1.3	3.7	2.7	2.3	0.5	100	2.1	4.5	C81
Non-Hodgkin lymphoma	325	0	2.1	1.9	0.7	1.8	2.9	2.1	3.1	5.2	4.9	7.8	7.4	11.5	23.1	23.0	43.0	62.7	57.7	21.9	10.6	2.3	100	6.7	0.6	C82-86,C96
Immunoproliferative diseases	15	0	–	–	–	–	–	–	–	0.9	–	–	1.0	1.3	1.4	0.6	1.1	1.3	3.7	–	0.5	0.1	100	0.3	5.4	C88
Multiple myeloma	138	0	–	–	–	–	–	–	0.4	–	1.3	2.1	4.0	8.1	10.0	9.7	21.5	33.3	26.1	1						

* Average percentage annual change since volume 11 (2008–2012). Significant changes (95% confidence level, Miettinen method, page 869 of volume 6) are marked in bold.

Poland, Kielce (2013–2017)

C15 Volume XII (editorial table 4)

ANNUAL INCIDENCE PER 100,000 BY AGE GROUP (YEARS) – FEMALE

S I T E	ALL AGE AGES	UNK	0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80–	85+	CRUDE RATE	(%)	MV (%)	ASR (W)	*CH V11	ICD (10th)
Lip	33	0	–	–	–	–	–	–	–	–	–	–	–	–	0.4	1.5	4.7	6.3	8.4	6.1	1.0	0.3	100	0.3	–3.4	C00
Tongue	25	0	–	–	–	–	–	–	–	0.9	0.5	1.1	1.0	0.8	1.2	3.0	2.3	2.4	0.9	–	0.8	0.2	96	0.4	6.9	C01-02
Mouth	43	0	–	–	–	–	–	0.5	0.4	–	0.5	0.5	1.5	2.5	3.7	3.0	4.7	3.2	2.8	2.0	1.3	0.4	100	0.7	7.8	C03-06
Salivary glands	24	0	–	–	–	–	–	–	0.4	–	0.5	1.1	–	0.8	0.8	1.5	3.1	1.6	6.6	–	0.7	0.2	100	0.3	0.3	C03-08
Tonsil	13	0	–	–	–	–	–	–	–	0.4	–	1.1	0.5	–	1.2	1.5	–	2.4	–	–	0.4	0.1	100	0.2	1.8	C09
Other oropharynx	13	0	–	–	–	–	–	–	–	–	0.5	–	1.5	0.4	1.2	0.5	1.6	1.6	–	–	0.4	0.1	100	0.2	0.5	C10
Nasopharynx	14	0	–	–	–	–	–	–	0.4	0.4	0.5	–	1.5	–	0.4	0.5	0.8	2.4	0.9	1.0	0.4	0.1	86	0.2	8.9	C11
Hypopharynx	10	0	–	–	–	–	–	–	–	0.4	–	–	0.5	0.8	0.4	0.5	0.8	1.6	0.9	–	0.3	0.1	100	0.2	1.7	C12-13
Pharynx unspecified	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.0	0.0	–	0.0	–	C14
Oesophagus	41	0	–	–	–	–	–	–	–	–	–	–	1.0	2.1	2.5	2.0	4.7	4.7	4.7	7.1	1.3	0.3	98	0.5	6.7	C15
Stomach	340	0	–	–	–	–	0.5	0.5	0.4	0.9	2.9	4.2	7.4	7.4	12.8	30.7	34.9	41.9	46.8	49.0	10.6	2.8	96	4.3	–4.1	C16
Small intestine	28	0	–	–	–	–	–	–	–	–	–	–	0.5	0.4	3.3	1.5	3.9	6.3	0.9	1.0	0.9	0.2	89	0.4	0.5	C17
Colon	818	0	–	–	–	–	0.5	0.9	1.2	4.3	4.8	11.1	21.3	25.2	43.0	57.3	85.3	109.1	98.4	98.0	25.4	6.7	97	10.7	–0.3	C18
Rectum	481	0	–	–	–	–	1.0	0.9	0.4	3.9	2.9	7.4	14.4	18.2	26.0	42.3	47.3	55.4	44.0	50.0	14.9	4.0	98	6.8	–1.7	C19-20
Anus	25	0	–	–	–	–	–	–	–	–	–	1.1	2.0	1.7	0.8	1.0	3.1	0.8	3.7	2.0	0.8	0.2	100	0.4	3.5	C21
Liver	174	0	–	0.7	–	–	–	0.5	–	0.9	0.5	1.6	5.0	2.9	9.5	11.1	14.0	24.5	22.5	31.7	5.4	1.4	69	2.2	7.0	C22
Gallbladder etc.	189	0	–	–	–	–	–	–	–	0.9	1.0	0.5	3.0	7.0	12.0	13.1	22.5	22.9	29.0	17.4	5.9	1.6	90	2.4	–8.9	C23-24
Pancreas	313	0	–	–	–	–	–	0.9	0.4	0.9	1.9	6.4	9.4	10.3	21.1	15.6	31.8	39.5	43.1	29.6	9.7	2.6	79	4.2	–0.4	C25
Nose, sinuses etc.	19	0	–	–	–	–	0.5	–	–	–	0.5	1.1	0.5	1.2	0.4	1.5	1.6	1.6	–	3.1	0.6	0.2	89	0.3	10.4	C30-31
Larynx	48	0	–	–	–	–	–	–	–	–	1.0	2.1	2.5	2.5	3.3	7.0	2.3	3.2	0.9	1.0	1.5	0.4	100	0.8	6.8	C32
Trachea, bronchus and lung	1076	0	–	–	–	–	–	0.5	0.8	1.7	2.4	12.7	20.8	58.3	98.0	121.7	105.5	92.5	77.8	42.9	33.4	8.9	94	15.7	3.2	C33-34
Other thoracic organs	20	0	–	–	–	–	–	0.5	–	–	–	–	1.5	0.8	0.8	1.0	1.6	2.4	1.9	3.1	0.6	0.2	80	0.3	9.8	C37-38
Bone	35	0	–	1.3	–	–	1.0	0.5	–	0.4	–	0.5	1.5	0.8	2.5	0.5	1.6	5.5	2.8	4.1	1.1	0.3	71	0.7	–9.1	C40-41
Melanoma of skin	359	0	–	–	–	1.9	0.5	0.9	6.2	5.6	7.6	9.0	16.9	17.0	16.5	22.6	22.5	30.0	31.9	31.7	11.1	3.0	100	5.9	5.4	C43
Other skin	1334	0	–	–	–	–	0.5	0.9	2.5	5.6	8.1	11.7	25.8	32.7	63.7	82.0	145.8	152.6	191.1	245.1	41.4	11.0	99	16.0	2.4	C44
Mesothelioma	31	0	–	–	–	–	–	–	–	–	–	1.1	2.0	2.5	1.7	3.5	1.6	2.4	1.9	1.0	1.0	0.3	100	0.5	–0.1	C45
Kaposi sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	0.5	–	–	–	–	–	–	1.0	0.1	0.0	100	0.0	–	C46
Connective and soft tissue	68	0	1.5	0.7	–	–	–	1.8	1.7	0.4	1.4	3.2	2.0	2.9	3.3	3.0	6.2	4.7	3.7	4.1	2.1	0.6	93	1.4	–5.2	C47+C49
Breast	2725	0	–	–	–	–	0.5	7.3	12.5	36.7	70.5	107.1	147.4	139.7	193.9	212.8	166.0	178.7	149.9	118.4	84.6	22.5	99	47.8	1.9	C50
Vulva	98	0	–	–	–	–	–	–	–	–	1.4	1.6	1.0	3.3	2.1	5.5	8.5	17.4	14.1	18.4	3.0	0.8	98	1.1	2.8	C51
Vagina	16	0	–	–	–	–	–	–	–	–	–	–	0.5	0.4	1.2	1.5	1.6	4.0	0.9	–	0.5	0.1	100	0.2	25.4	C52
Cervix uteri	380	0	–	–	–	–	0.5	0.9	5.4	3.5	10.5	18.6	23.8	19.0	27.3	18.1	24.0	25.3	27.2	11.2	11.8	3.1	98	6.9	–6.1	C53
Corpus uteri	1099	0	–	–	–	–	0.5	–	0.4	1.3	9.5	20.7	51.6	66.6	88.0	97.1	115.6	87.8	66.5	33.7	34.1	9.1	99	17.3	2.0	C54
Uterus unspecified	12	0	–	–	–	–	–	–	–	–	0.5	–	–	0.4	0.5	–	–	–	3.7	4.1	0.4	0.1	50	0.1	–7.3	C55
Ovary	638	0	0.7	–	0.7	1.9	2.5	1.4	1.7	5.6	13.8	22.8	31.3	35.1	41.7	54.3	38.8	48.2	36.5	29.6	19.8	5.3	94	11.1	1.5	C56
Other female genital organs	12	0	–	–	–	–	–	–	–	–	–	0.5	–	1.7	0.4	0.5	0.8	0.8	–	3.1	0.4	0.1	83	0.2	–14.4	C57
Placenta	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.0	0.0	–	0.0	–	C58
Kidney	388	0	2.2	2.7	–	–	–	–	1.2	0.4	4.3	5.8	13.4	17.8	22.7	37.7	42.7	42.7	29.0	17.4	12.0	3.2	94	6.2	1.3	C64
Renal pelvis	28	0	–	–	–	–	–	–	–	–	–	0.5	0.5	0.8	2.9	5.5	1.6	1.6	0.9	1.0	0.9	0.2	100	0.4	19.1	C65
Ureter	10	0	–	–	–	–	–	–	–	–	–	–	–	–	0.8	2.0	0.8	1.6	–	1.0	0.3	0.1	100	0.1	12.9	C66
Bladder	302	0	–	–	–	–	1.5	1.4	–	0.4	1.0	3.7	6.0	14.1	19.4	25.2	36.5	25.3	32.8	29.6	9.4	2.5	97	4.2	1.3	C67
Other urinary organs	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1.6	–	–	0.1	0.0	100	0.0	–16.4	C68
Eye	50	0	1.5	–	–	–	0.5	0.5	0.4	1.3	0.5	1.6	–	2.5	2.9	3.5	2.3	3.2	6.6	4.1	1.6	0.4	76	0.9	3.6	C69
Brain, nervous system	264	0	2.2	1.3	1.4	0.6	2.0	1.8	0.4	2.6	5.2	6.4	3.0	15.7	13.2	18.1	21.7	27.7	21.5	20.4	8.2	2.2	69	4.5	–4.4	C70-72
Thyroid	705	0	–	–	1.4	5.6	12.5	17.3	23.3	29.3	38.6	37.1	34.2	27.3	27.3	37.7	32.6	17.4	6.6	9.2	21.9	5.8	99	16.6	8.3	C73
Adrenal gland	7	0	1.5	0.7	0.7	–	–	–	–	0.4	–	0.5	–	–	0.4	–	–	–	–	–	0.2	0.1	86	0.4	3.8	C74
Other endocrine	5	0	–	–	–	–	–	–	0.4	–	–	–	0.5	–	0.4	0.5	0.8	–	–	–	0.2	0.0	100	0.1	–4.0	C75
Hodgkin lymphoma	67	0	–	0.7	0.7	2.5	5.5	3.6	3.3	1.7	3.8	0.5	1.0	1.2	1.7	1.0	2.3	4.0	0.9	1.0	2.1	0.6	100	1.9	3.6	C81
Non-Hodgkin lymphoma	274	0	0.7	0.7	0.7	0.6	1.0	0.9	3.3	2.2	2.9	5.8	7.9	12.4	13.6	14.6	20.9	34.8	34.7	20.4	8.5	2.3	100	4.2	1.4	C82-86,C96
Immunoproliferative diseases	7	0	–	–	–	–	–	–	–	–	–	–	–	0.4	0.8	0.5	0.8	0.8	–	1.0	0.2	0.1	100	0.1	–19.2	C88
Multiple myeloma	146	0	–	–	–	–	–	0.5	–	0.4	2.4	3.7	3.0	2.9	8.7	12.1	17.8	17.4	18.7	9.2	4.5	1.2	100	2.1	–1.1	C90
Lymphoid leukaemia	209	0	1.5	2.7	0.7	0.6	1.5	0.5	0.4	0.4	1.0	4.2	4.0	4.1	9.5	15.1	20.9	26.1	25.3	27.6	6.5	1.7	100	3.2	–4.7	C91
Myeloid leukaemia	126	0	1.5	–	2.1	–	–	–	1.7	1.7	1.4	2.7	4.0	7.0	3.3	5.5	10.1	14.2	12.2	17.4	3.9	1.0	99	2.1	–1.6	C92-94
Leukaemia unspecified	10	0	–	–	–	–	–	–	–	–	–	–	0.5	0.4	–	–	3.1	–	3.7	–	0.3	0.1	90	0.1	–6.1	C95
Myeloproliferative disorders	56	0	–	–	–	–	0.5	–	0.4	0.4	–	–	1.0	2.5	2.5	3.5	7.0	7.1	9.4	4.1	1.7	0.5	100	0.7	1.8	MPD
Myelodysplastic syndromes	7	0	–	–	–	–	–	–	–	–	–	–	–	0.4	0.8	0.5	1.6	–	0.9	–	0.2	0.1	100	0.1	29.8	MDS
Other and unspecified	252	0	0.7	–	–	–	1.0	–	–	–	1.4	1.1														

Poland, Kielce (2013–2017)
National comparison and M/I ratios
CI5 Volume XII (editorial table 5)

MALE

S I T E	Cases	ASR (se)	O/E	MV(%)	DCO(%)	M/I(%)	ICD-10
Lip, oral cavity and pharynx	547	10.5 (0.46)	1.03	98.2	–	60.1	C00–14
Oesophagus	190	3.6 (0.27)	0.98	96.8	–	91.6	C15
Stomach	642	11.4 (0.47)	0.87	95.8	0.2	92.1	C16
Colon, rectum and anus	1811	31.4 (0.77)	0.94	97.9	–	61.8	C18–21
Liver	235	4.2 (0.29)	1.13	71.5	–	70.2	C22
Gallbladder etc.	106	1.9 (0.19)	0.92	81.1	–	84.9	C23–24
Pancreas	311	5.6 (0.33)	0.81	82.3	–	119.3	C25
Larynx	368	6.8 (0.36)	0.85	99.2	–	66.0	C32
Lung (incl. trachea)	2859	50.2 (0.96)	0.93	94.1	–	100.2	C33–34
Melanoma of skin	299	5.7 (0.34)	1.14	99.7	–	50.5	C43
Prostate	2950	50.4 (0.95) >	1.34	97.4	–	30.4 <	C61
Testis	190	5.4 (0.41)	1.13	97.9	–	11.1	C62
Kidney etc.	595	11.4 (0.50)	0.92	95.5	–	49.4	C64–66,C68
Bladder	1116	19.1 (0.59)	0.91	97.5	–	46.7 >	C67
Brain, central nervous system	310	6.7 (0.42)	0.95	76.8	–	94.2	C70–72
Thyroid	137	3.1 (0.28)	1.78	99.3 >	–	14.6	C73
Lymphoma	549	11.5 (0.55)	1.14	99.8	–	60.1	C81–88,C90
Leukaemia	436	9.3 (0.52)	1.12	99.5	0.2	63.3	C91–95
Ill-defined (1.8% of total)	251	4.3 (0.28) <	0.52	76.1	–	162.2	C76–80
All sites except skin	14295	260.8 (2.30)	1.00	95.1	0.0	65.6	C00–96bC44

FEMALE

S I T E	Cases	ASR (se)	O/E	MV(%)	DCO(%)	M/I(%)	ICD-10
Lip, oral cavity and pharynx	175	2.6 (0.22)	1.01	98.3	–	49.1	C00–14
Oesophagus	41	0.5 (0.09)	0.84	97.6	–	104.9	C15
Stomach	340	4.3 (0.27)	0.86	96.2	–	87.9	C16
Colon, rectum and anus	1324	17.8 (0.55)	0.99	97.7	–	63.4	C18–21
Liver	174	2.2 (0.20)	1.13	69.0	–	97.1	C22
Gallbladder etc.	189	2.4 (0.19)	0.78	90.5	–	111.1	C23–24
Pancreas	313	4.2 (0.27)	0.95	78.6	–	124.3	C25
Larynx	48	0.8 (0.13)	1.18	100.0	–	43.8	C32
Lung (incl. trachea)	1076	15.7 (0.51)	1.04	93.7	0.1	88.2	C33–34
Melanoma of skin	359	5.9 (0.36)	1.34	100.0	–	37.9	C43
Breast	2725	47.8 (1.00)	1.01	98.7	0.0	34.6	C50
Cervix uteri	380	6.9 (0.39) <	0.74	98.4	–	66.3 >	C53
O&U part of uterus	1111	17.4 (0.56)	1.15	98.2	–	28.3	C54–55
Ovary	638	11.1 (0.49)	1.05	94.0	–	64.3	C56
Kidney etc.	428	6.8 (0.39)	1.15	94.4	–	32.2	C64–66,C68
Bladder	302	4.2 (0.27)	1.03	97.4	–	37.1	C67
Brain, central nervous system	264	4.5 (0.35)	0.84	69.3	–	86.0	C70–72
Thyroid	705	16.6 (0.67)	2.25	99.3	–	5.5	C73
Lymphoma	494	8.3 (0.45)	1.08	100.0	–	61.7	C81–88,C90
Leukaemia	345	5.4 (0.39)	1.08	99.4	0.3	60.3	C91–95
Ill-defined (1.9% of total)	226	2.4 (0.18) <	0.49	70.8	–	181.4	C76–80
All sites except skin	12137	195.8 (2.02)	1.05	95.2	0.0	55.6	C00–96bC44

Data compared with that from 6 cancer registries in Poland. (See list next page)

Significant lower (<) or higher (>) changes are marked in bold.

Mortality data: official statistics

The detail description of the statistical tests can be found in the 'Comparability and quality of data' chapter of CI5 Vol. 8 (page 72)

Poland, Kielce (2013–2017)
National comparison and M/I ratios
CI5 Volume XII (editorial table 5)

Cancer registries used for comparison:

1. Poland, Cracow (2008–2012)
2. Poland, Lower Silesia (2008–2012)
3. Poland, Kielce (2008–2012)
4. Poland, Poznan (2008–2012)
5. Poland, Lublin (2008–2012)
6. Poland, Podkarpackie (2008–2012)

Top 10 cancers, ASR (World) per 100,000

MALE		FEMALE	
Prostate	50.4	Breast	47.8
Trachea, bronchus and lung	50.2	Corpus uteri	17.3
Non-melanoma skin cancer	20.3	Thyroid	16.6
Bladder	19.1	Non-melanoma skin cancer	16.0
Colon	17.2	Trachea, bronchus and lung	15.7
Rectum	14.0	Ovary	11.1
Stomach	11.4	Colon	10.7
Kidney	10.5	Cervix uteri	6.9
Larynx	6.8	Rectum	6.8
Brain, nervous system	6.7	Kidney	6.2
All sites	281.2	All sites	211.8